CERA

Science and Research

MERIT: Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial

The MERIT Trial was designed to find out which intravitreal therapy offers the best balance of effectiveness and tolerability in treating persistent or recurrent uveitic macular edema, in eyes with controlled uveitis but persistent macular edema. 

Overview

The MERIT Trial was designed to find out which intravitreal therapy offers the best balance of effectiveness and tolerability in treating persistent or recurrent uveitic macular edema, in eyes with controlled uveitis but persistent macular edema.

Specifically, it is comparing the relative efficacy and safety of intravitreal ranibizumab (Lucentis) and intravitreal methotrexate to intravitreal dexamethasone implant (Ozurdex) for the treatment of persistent /recurrent uveitic macular edema.

  • Principal Investigator
Associate Professor Lyndell Lim

Learn more

View this study at ClinicalTrials.gov

This international database listing provides more detailed information about this study.